Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease

References

• Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951 Mar 01;27(2):277–301.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. [cited 2012 Oct 10].
   PubMed Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthritis Rheum. 2013;65(1):270–281. [cited 2012 Oct 10].
   PubMed Web of Science ®Google Scholar
• Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016 Nov 02;48(5):1429–1441.
   PubMedGoogle Scholar
• Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med. 2015 May 15;26(7):545–553.
   PubMed Web of Science ®Google Scholar
• Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926-2935.
   PubMedGoogle Scholar
• Szczeklik W, Sokolowska BM, Zuk J, et al. The course of asthma in Churg-Strauss syndrome. J Asthma. 2011 Jan 21;48(2):183–187.
   PubMed Web of Science ®Google Scholar
• Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med. 2006 Apr 14;27(2):148–157.
   PubMed Web of Science ®Google Scholar
• Durel CA, Berthiller J, Caboni S, et al. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (churg-strauss). Arthritis Care Res. 2016 Sep 01;68(3):374–387.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort. Med. 2011 Jan 05;90(1):19–27.
   PubMed Web of Science ®Google Scholar
• Samson M, Puechal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013 Apr 18;43:60–69.
   PubMed Web of Science ®Google Scholar
• Hattori N, Mori K, Misu K, et al. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol [Internet]. 2002 Jul;29(7):1408–1414. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12136898
   PubMed Web of Science ®Google Scholar
• Puéchal X, Pagnoux C, Baron G, et al. Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.  Rheumatology (Oxford). 2019 Dec 1;58(12):2107–2116. doi: 10.1093/rheumatology/kez139.
   Google Scholar
• Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Med. 1999;78(1): 26–37. 1999/02/17.
   PubMed Web of Science ®Google Scholar
• Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011–1017. 2012/08/14.
   PubMed Web of Science ®Google Scholar
• Latorre M, Baldini C, Seccia V, et al. Asthma control and airway inflammation in patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pr. 2016;4(3):512–519. 2016/02/18.
   PubMed Web of Science ®Google Scholar
• Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy Eur J Allergy Clin Immunol. 2009;64(4):589-595.
   Google Scholar
• Berti A, Specks U, Keogh KA, et al. Current and future treatment options for eosinophilic granulomatosis with polyangiitis. Curr Treat Options Rheumatol [Internet]. 2017;34:193–206.
   Google Scholar
• Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003 Sep 12;115(4):284–290.
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Tsuburai T, Saito H, et al. A retrospective study of bronchial hyperresponsiveness in patients with asthma before the onset of Churg-Strauss syndrome. Allergy Asthma Proc. 2007 Jul 11;28(3):336–343.
   PubMed Web of Science ®Google Scholar
• Berti A, Volcheck GW, Cornec D, et al. Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respir Med [Internet]. 2018;142:66–72.
   PubMed Web of Science ®Google Scholar
• Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: A case-crossover study. Thorax. 2008;63(8):677-682.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708-713.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Wong DA, Miller MK, et al. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136(2):507-518.
   PubMed Web of Science ®Google Scholar
• Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008;121(1):253-254.
   PubMed Web of Science ®Google Scholar
• Bottero P, Bonini M, Vecchio F, et al. The common allergens in the Churg-Strauss syndrome. Allergy. 2007 Oct 09;62(11):1288–1294.
   PubMed Web of Science ®Google Scholar
• Nakamoto K, Saraya T, Ogawa Y, et al. Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. Respir Med. 2018 Jun 03;139:101–105.
   PubMed Web of Science ®Google Scholar
• Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126(5):503-509.
   PubMed Web of Science ®Google Scholar
• Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis. 2012;71(3):390–393. [cited 2011 Nov 29].
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Saito H, Tsuburai T, et al. Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol. 2008 Jul 01;122(3):610–616.
   PubMed Web of Science ®Google Scholar
• Jakiela B, Szczeklik W, Plutecka H, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatol. 2012 Jul 10;51(10):1887–1893.
   PubMed Web of Science ®Google Scholar
• Jakiela B, Sanak M, Szczeklik W, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. 2011 Apr 08;29(1 Suppl 64):S23–34.
   PubMed Web of Science ®Google Scholar
• Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc. 1977;52(8):477-484.
   PubMed Web of Science ®Google Scholar
• Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Med. 1984 Mar 01;63(2):65–81.
   PubMed Web of Science ®Google Scholar
• Oka N, Kawasaki T, Matsui M, et al. Two subtypes of Churg-Strauss syndrome with neuropathy: the roles of eosinophils and ANCA. Mod Rheumatol. 2011;21(3):290-295.
   Web of Science ®Google Scholar
• Healy B, Bibby S, Steele R, et al. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol. 2013;131(2):571-6.e1-6.
   PubMed Web of Science ®Google Scholar
• Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on e. Autoimmun Rev. 2017;16(1):1–9. [cited 2016 Oct 28].
   PubMed Web of Science ®Google Scholar
• Grayson PC, Monach PA, Pagnoux C, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatol (United Kingdom). 2015;54(8):1351-1359.
   Google Scholar
• Meziane H, Maakel ML, Vachier I, et al. Sputum eosinophilia in Churg-Strauss syndrome. Respir Med. 2001;95(10):799-801.
   PubMed Web of Science ®Google Scholar
• Groh M, Masciocco G, Kirchner E, et al. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J Heart Lung Transplant. 2014; 33(8):842-850.
   PubMed Web of Science ®Google Scholar
• Rohmer J, Groh M, Samson M, et al. Distal ischemia as the initial presentation of hypereosinophilic syndrome-related arterial involvement: A case study and literature review. Autoimmun Rev. 2019;18(8):828-830.
   PubMed Web of Science ®Google Scholar
• Marx C, Novotny J, Salbeck D, et al. Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis by eosinophil extracellular traps. Blood. 2019;134(21):1859-1872.
   Google Scholar
• Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019 Nov 12;10(1):5120. doi:10.1038/s41467-019-12515-9
   Google Scholar
• Wieczorek S, Hellmich B, Gross WL, et al. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al [1]. Arthritis Rheumatism. 2008;58(1):329-330.
   Google Scholar
• Wieczorek S, Hellmich B, Arning L, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener’s granulomatosis. Arthritis Rheum. 2008;58(6):1839-1848.
   Google Scholar
• Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. 2007;56(9):3159-3166.
   PubMedGoogle Scholar
• Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850-873.
   Web of Science ®Google Scholar
• Lefèvre G, Copin MC, Staumont-Sallé D, et al. The lymphoid variant of hypereosinophilic syndrome study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Med (United States). 2014;93(17):255-266.
   Google Scholar
• Emmi G, Silvestri E, Marconi R, et al. First report of FIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis. Rheumatol (United Kingdom). 2015;54(9):1751-1753.
   Google Scholar
• Matthieu G, Jean-Emmanuel K, Puéchal Xavier GL. Comment on: first report of FIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis. Rheumatol. 2016;55(2):384–385.
   PubMed Web of Science ®Google Scholar
• Leurs A, Chenivesse C, Lopez B, et al. C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody–negative eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract [Internet]. 2019 Apr 1;7(4):1347–1351.e3. [cited 2019 Jul 18]. Available from: https://www.jaci-inpractice.org/article/S2213-2198(18)30659-7/abstract#.XTDTATyYZjo.mendeley
   PubMed Web of Science ®Google Scholar
• Puechal X, Pagnoux C, Baron G, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis or polyarteritis nodosa without poor prognosis factors a randomized-controlled trial. Arthritis Rheumatol. 2017 Jul 06;69(11):2175-2186.
   Web of Science ®Google Scholar
• Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: A retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005;84(5):323-330.
   PubMed Web of Science ®Google Scholar
• Berti A, Cornec D, Casal Moura M. Eosinophilic Granulomatosis with Polyangiitis: clinical predictors of long-term asthma severity. Chest. Accepted for publication on November 30, 2019.
   Google Scholar
• Sokołowska B, Szczeklik W, Włudarczyk A, et al. ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single polish centre. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S41-7.
   PubMed Web of Science ®Google Scholar
• Pelà G, Tirabassi G, Pattoneri P, et al. Cardiac Involvement in the Churg-Strauss Syndrome. Am J Cardiol. 2006;97(10):1519-1524.
   PubMedGoogle Scholar
• Hazebroek MR, Dennert R, Bektas S, et al. Cardiac involvement in Churg-Strauss syndrome and granulomatosis with polyangiitis (Wegeners). Eur Heart J. 2013;34(suppl 1):P5714-P5714.
   Web of Science ®Google Scholar
• Neumann T, Manger B, Schmid M, et al. Cardiac involvement in churg-strauss syndrome: impact of endomyocarditis. Medicine (Baltimore). 2009;88(4):236-243.
   PubMedGoogle Scholar
• Dunogué B, Terrier B, Cohen P, et al. Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. Autoimmun Rev. 2015;14(9):774-780.
   Web of Science ®Google Scholar
• Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009 ;68(4):564–567. [cited 2008 Nov 19]
   PubMed Web of Science ®Google Scholar
• Berti A, Matteson EL, Crowson CS, et al. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: A 20-year population-based cohort study. Mayo Clin Proc. 2018 Mar 29;93(5):597–606.
   PubMed Web of Science ®Google Scholar
• André R, Cottin V, Saraux JL, et al. Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): report of 26 patients and review of the literature. Autoimmun Rev. 2017;16(9):963-969.
   PubMed Web of Science ®Google Scholar
• Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990 Aug 01;33(8):1094–1100.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017 May 18;376(20):1921–1932.
   PubMed Web of Science ®Google Scholar
• Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612.e9.
   Web of Science ®Google Scholar
• Craven A, Robson J, Ponte C, et al. ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin Exp Nephrol. 2013;17(5):619-621.
   PubMed Web of Science ®Google Scholar
• Robson JC, Grayson PC, Ponte C, et al. OP0021 Draft classification criteria for the anca associated vasculitides. Ann Rheum Dis. 2018;77:60-61.
   Google Scholar
• Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: A multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586-594.
   PubMedGoogle Scholar
• Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Care Res. 2007;57(4):686-693.
   Web of Science ®Google Scholar
• Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Med. 1996 Jan 01;75(1):17–28.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 04;349(1):36–44.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790-2803.
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. Jama. 2010 Nov 10;304(21):2381–2388.
   PubMed Web of Science ®Google Scholar
• Berti A, Scotti R, Rizzo N, et al. Kaposi's Sarcoma in a Patient with Eosinophilic Granulomatosis with Polyangiitis While Taking Mycophenolate Mofetil. J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):431–432. doi: 10.1016/j.jaip.2014.11.023.
   Google Scholar
• Schandené L, Del Prete GFF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest. 1996;7(2):309-315.
   PubMed Web of Science ®Google Scholar
• Aldebert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for interferon α: inhibitory role of interferon α on the release of mediators. Blood. 1996; 87(6):2354-2360.
   PubMed Web of Science ®Google Scholar
• Seeliger B, Förster M, Happe J, et al. Interferon-α for induction and maintenance of remission in eosinophilic granulomatosis with polyangiitis: A single-center retrospective observational cohort study. J Rheumatol. 2017;44(6):806-814.
   PubMed Web of Science ®Google Scholar
• Crickx E, Machelart I, Lazaro E, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French Nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68(3):702-712.
   PubMed Web of Science ®Google Scholar
• Danieli MG. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004;63(12):1649-1654.
   PubMed Web of Science ®Google Scholar
• Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol. 2016 Mar 08;68(9):2274–2282.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 22;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• Specks U, Merkel PA, Seo P, et al.  Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 1;369(5):417–427. doi: 10.1056/NEJMoa1213277.
   Google Scholar
• Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum. 2012 Jun 26;64(11):3770–3778.
   PubMedGoogle Scholar
• Thiel J, Hassler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013 Nov 30;15(5):R133.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75(2):396–401. [cited 2014 Dec 04].
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336-1343.
   Google Scholar
• Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing churg-strauss syndrome. Ann Intern Med. 2011;155(5):341-343.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. (80-). 2017/11/04. 2018;359(6371):97–103.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2017;69(8):1521-1537.
   Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318.
   Google Scholar
• Groh M, Puéchal X, Terrier B, et al. Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: the pneumovas pilot 1 study. Joint Bone Spine. 2017;84(5):643-644.
   Web of Science ®Google Scholar
• Jeffs LS, Peh CA, Jose MD, et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology. 2015;20(5):343-351.
   Web of Science ®Google Scholar
• Kernéis S, Turbelin C, Pagnoux C, et al. Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S89-92.
   PubMed Web of Science ®Google Scholar
• Charles P, Bienvenu B, Bonnotte B, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Press Med. 2013;42(10):1317-1330.
   Web of Science ®Google Scholar
• McGeoc L, Twilt M, Famorca L, et al. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol. 2016;43(1):97-120.
   Web of Science ®Google Scholar